Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 2/20 | 0.61 |
| ▸ | CASP6 | P55212 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887329 | 1.00 | MEN1 (0.71) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL17779690 | 0.93 | AKR1B1 (0.63) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL20837934 | 0.93 | AKR1B1 (0.63) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL20837903 | 0.92 | MEN1 (0.75) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL17779681 | 0.92 | MEN1 (0.75) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL31284000 | 0.89 | PTPN1 (0.61) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL18102843 | 0.89 | AKR1B1 (0.58) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL31283784 | 0.89 | PTPN1 (0.61) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL12008449 | 0.89 | TAS2R14 (0.76) | MEN1KMT2APOLBPSMD14MAPT | |
| SCHEMBL9393527 | 0.88 | PDE4B (0.78) | MEN1KMT2APOLBAKR1B1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES (FR) | 2022-06-02 | — | — | US | claimed |
| EP-3947355-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres (FR) | 2022-02-09 | — | — | EP | claimed |
| WO-2020201538-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES – QUARTIER LATIN (FR) | 2020-10-08 | — | — | WO | claimed |
| EP-3719007-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-10-07 | — | — | EP | claimed |
| EP-4584590-A1 | PROXIMITY INDUCING SYSTEM AND USES THEREOF | SORBONNE UNIVERSITE (FR) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052353-A1 | PROXIMITY INDUCING SYSTEM AND USES THEREOF | SORBONNE UNIVERSITE (FR) | 2024-03-14 | — | — | WO | disclosed |
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES (FR) | 2022-06-02 | — | — | US | disclosed |
| EP-3947355-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres (FR) | 2022-02-09 | — | — | EP | disclosed |
| US-11162951-B2 | Membrane-impermeant fluorogenic chromophores | PARIS SCIENCES ET LETTRES (FR) | 2021-11-02 | — | — | US | disclosed |
| WO-2020201538-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES – QUARTIER LATIN (FR) | 2020-10-08 | — | — | WO | disclosed |
| EP-3404022-B1 | MEMBRANE-IMPERMEANT FLUOROGENIC CHROMOPHORES | PARIS SCIENCES LETTRES QUARTIER LATIN (FR) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719007-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-10-07 | — | — | EP | disclosed |
| US-20200124611-A1 | MEMBRANE-IMPERMEANT FLUOROGENIC CHROMOPHORES | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-04-23 | — | — | US | disclosed |
| WO-2018211090-A1 | MEMBRANE-IMPERMEABLE FLUOROGENIC CHROMOPHORES | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2018-11-22 | — | — | WO | disclosed |
| EP-3404022-A1 | MEMBRANE-IMPERMEABLE FLUOROGENIC CHROMOPHORES | Paris Sciences et Lettres - Quartier Latin (FR) | 2018-11-21 | — | — | EP | disclosed |
| US-6673816-B1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | Esswein, Angelika (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200124611-A1 | MEMBRANE-IMPERMEANT FLUOROGENIC CHROMOPHORES | QRFPR, BLVRB, IK | MEN1 3340/4885KMT2A 2506/4885POLB 3419/4885 |
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | BLVRB, IK, HBG2 | MEN1 3845/4885KMT2A 1217/4885POLB 1720/4885 |
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | NR1H4, NR1D1, NR1I2 | MEN1 838/4885KMT2A 1995/4885POLB 2514/4885 |
| US-11162951-B2 | Membrane-impermeant fluorogenic chromophores | QRFPR, BLVRB, IK | MEN1 3340/4885KMT2A 2506/4885POLB 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.